Dr. Molly He the CEO and co-founder of Element Biosciences, a multi-disciplinary life science company democratizing access to advanced DNA and multi-omic sequencing solutions.  Since the inception of Element in 2017, Molly and her team have raised over $600M to fund the development, manufacturing, and commercialization of disruptive sequencing tools, including AVITI and AVITI24. Molly has won numerous awards including the prestigious Forbes 50over50 in 2023, and CNBC Changemaker in 2024.  Previously, Molly was a Venture Partner at Foresite Capital Management.  Before Foresite, Molly was a Senior Director at Illumina, responsible for Illumina’s global protein reagent innovation and improvements.  She had led a team to win twice the Innovation Award, the highest award for innovations with significant revenue impact at Illumina.  Before Illumina, Molly was the Head of Protein Sciences at Pacific Biosciences responsible for protein reagent development to improve the accuracy of their single molecular real time sequencing chemistry.  Molly is a prolific inventor with more than one hundred patent applications, including many in the field of genomics and protein sciences.  Molly holds a PhD from UCLA in protein biophysics.